Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565006 | 0.84 | HCAR2 (0.47) | NAPRTALDH1A1GAAMAPTLMNA | |
| SCHEMBL439096 | 0.84 | HCAR2 (0.47) | NAPRTALDH1A1GAAMAPTLMNA | |
| Hydrochloric Acid SCHEMBL2704937 | 0.82 | HCAR2 (0.46) | NAPRTALDH1A1GAAMAPTLMNA | |
| SCHEMBL9192729 | 0.82 | ALDH1A1 (0.39) | ALDH1A1GAAMAPTCHRNB2CHRNA4 | |
| Hydrazine SCHEMBL27966259 | 0.81 | HCAR2 (0.44) | NAPRTALDH1A1GAAMAPTLMNA | |
| SCHEMBL9865820 | 0.80 | TTR (0.38) | NAPRTALDH1A1GRM4 | |
| SCHEMBL29838220 | 0.79 | KMT2A (0.46) | NAPRTALDH1A1KMT2A | |
| SCHEMBL991416 | 0.79 | KMT2A (0.46) | NAPRTALDH1A1KMT2A | |
| SCHEMBL28445897 | 0.78 | HDAC1 (0.34) | NAPRTALDH1A1LMNAGRM4HTT | |
| SCHEMBL10386997 | 0.78 | HTT (0.50) | NAPRTGRM4HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
| CN-108299400-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-06 | — | — | US | disclosed |
| EP-3345902-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart NeuroScience (Cayman) Ltd (KY) | 2018-07-11 | — | — | EP | disclosed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | disclosed |
| WO-2017004608-A1 | OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| CN-101522626-A | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN LA ROCHE (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| EP-1868999-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | NAPRT 1318/4885ALDH1A1 1288/4885GAA 1932/4885 |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | NAPRT 1318/4885ALDH1A1 1288/4885GAA 1932/4885 |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | NAPRT 3243/4885ALDH1A1 1799/4885GAA 1742/4885 |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | NAPRT 1058/4885ALDH1A1 2693/4885GAA 3655/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | NAPRT 3243/4885ALDH1A1 1799/4885GAA 1742/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | NAPRT 1318/4885ALDH1A1 1288/4885GAA 1932/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | NAPRT 1334/4885ALDH1A1 1356/4885GAA 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.